EF Hutton analyst Tony Butler downgraded Aravive to Hold from Buy with a price target of $1, down from $10, after the Phase 3 trial of batiraxcept in combination with paclitaxel to treat platinum-resistant ovarian cancer did not meet the primary endpoint of progression-free survival. The firm says its net present values on ovarian cancer for batiraxcept are now eliminated and that the company’s current cash is insufficient at this time to support funding for an additional trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARAV:
- Aravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian Cancer
- Aravive downgraded to Neutral from Buy at H.C. Wainwright
- Aravive downgraded to Neutral from Buy at BTIG
- Aravive says Phase 3 AXLerate-OC trial did not meet primary endpoint
- Aravive trading resumes
Questions or Comments about the article? Write to editor@tipranks.com